<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969497</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2021-001</org_study_id>
    <nct_id>NCT04969497</nct_id>
  </id_info>
  <brief_title>Study of PK, Safety, and Tolerability of 2 Lots of M207 &amp; Intranasal Zolmitriptan in Healthy Volunteers</brief_title>
  <official_title>A Randomized Open-Label Three-Way Crossover Study to Compare the Pharmacokinetics, Safety, and Tolerability of Two Lots of M207 3.8 mg (Administered as Two 1.9 mg Patches on the Upper Arm for 30 Minutes) and Intranasal Zolmitriptan 5.0 mg x 2 Doses in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zosano Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zosano Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized, 3-way crossover study. Each subject will&#xD;
      receive each of the three study treatments once, followed by in-clinic monitoring and&#xD;
      extensive blood sample collection for plasma PK analysis.&#xD;
&#xD;
      Dosing will occur at least 48 hours apart from the time of patch application, until&#xD;
      completion of dosing in randomized order per the treatment sequence schedule. After&#xD;
      completion dosing, subjects will be assessed one final time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, randomized, three-way crossover study. Each subject will&#xD;
      receive each of the three study treatments once, followed by in-clinic monitoring and&#xD;
      extensive blood sample collection for pharmacokinetic analysis.&#xD;
&#xD;
      Dosing will occur at least 48 hours apart from the time of patch application, until&#xD;
      completion of dosing in randomized order per the treatment sequence schedule. Subjects may be&#xD;
      dosed in 2 or more separate groups in each period, for example, 24 subjects on one day and 24&#xD;
      subjects on another day.&#xD;
&#xD;
      Plasma samples from the dosing days will be sent to the analytical laboratory for analysis.&#xD;
      Tolerability scores for each of the dose levels will be summarized.&#xD;
&#xD;
      After completion of the three dosing days, subjects will be assessed one final time and&#xD;
      dismissed from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2021</start_date>
  <completion_date type="Actual">September 2, 2021</completion_date>
  <primary_completion_date type="Actual">September 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects are randomized to receive one of six treatment sequences of three open-label treatments 48 hours apart.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence and type of adverse events reported and observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximum observed plasma concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 hours</time_frame>
    <description>Time in hours to maximum concentration assessed over 24 hours</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives interventions in the sequence, A, B, C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives interventions in the sequence, C, A, B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives interventions in the sequence, B, C, A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence CBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives interventions in the sequence, C, B, A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives interventions in the sequence, B, A, C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives interventions in the sequence, A, C, B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A: M207 3.8 mg &quot;MiniMac&quot;</intervention_name>
    <description>Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a &quot;MiniMac&quot; coater and packaged in foil cups</description>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_label>Sequence ACB</arm_group_label>
    <arm_group_label>Sequence BAC</arm_group_label>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_label>Sequence CAB</arm_group_label>
    <arm_group_label>Sequence CBA</arm_group_label>
    <other_name>MiniMac</other_name>
    <other_name>M207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B: M207 3.8 mg &quot;MACAP&quot;</intervention_name>
    <description>Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a &quot;MACAP&quot; coater and packaged in foil cups</description>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_label>Sequence ACB</arm_group_label>
    <arm_group_label>Sequence BAC</arm_group_label>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_label>Sequence CAB</arm_group_label>
    <arm_group_label>Sequence CBA</arm_group_label>
    <other_name>MACAP</other_name>
    <other_name>M207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0</intervention_name>
    <description>Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0</description>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_label>Sequence ACB</arm_group_label>
    <arm_group_label>Sequence BAC</arm_group_label>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_label>Sequence CAB</arm_group_label>
    <arm_group_label>Sequence CBA</arm_group_label>
    <other_name>Zomig</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women or men 18 to 50 years of age (inclusive)&#xD;
&#xD;
          2. Good general health with no clinically significant abnormalities as determined by&#xD;
             medical history, physical examination, CBC, blood chemistry, urinalysis, and ECG.&#xD;
&#xD;
          3. Negative serum pregnancy tests (for female subjects) at the screening and admission&#xD;
             visit.&#xD;
&#xD;
          4. Consent of female subjects to use a medically effective method of contraception&#xD;
             throughout the entire study period and for 30 days after the subject completes the&#xD;
             study. Medically effective methods of contraception that may be used by the subject&#xD;
             include abstinence, use of diaphragm and spermicide, intrauterine device (IUD), rings,&#xD;
             condom and vaginal spermicide, non-oral hormonal contraceptives (subjects must be&#xD;
             stable on non-oral hormonal contraceptives for at least 3 months prior to screening),&#xD;
             surgical sterilization (hysterectomy, bilateral tubal ligation or oophorectomy,&#xD;
             hysteroscopic sterilization) and post-menopausal (â‰¥ 2 years of amenorrhea).&#xD;
&#xD;
          5. Ability to read, understand, and provide written informed consent that they understand&#xD;
             the purpose of the study and procedures required for the study before enrolling in the&#xD;
             study, and willingness to comply with all study procedures and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of significant history of hepatic, reproductive, gastrointestinal, renal,&#xD;
             bleeding, or hematological disorders including coagulation, pulmonary, neurological,&#xD;
             respiratory, endocrine, or cardiovascular system abnormalities (especially&#xD;
             hypertension, peripheral vascular disease, coronary artery disease, transient ischemic&#xD;
             attacks, or cardiac rhythm abnormalities), psychiatric disorders, acute infection, or&#xD;
             other conditions that would interfere with study participation or with the absorption,&#xD;
             distribution, metabolism, or excretion of drugs.&#xD;
&#xD;
          2. Presence of three or more of the following CAD risk factors for cardiovascular&#xD;
             disease:&#xD;
&#xD;
             A. Current tobacco use (subjects who have smoked within 30 days of screening) B.&#xD;
             Hypertension (systolic BP &gt; 140 or diastolic BP &gt; 90) or receiving anti-hypertensive&#xD;
             medication for treatment of hypertension C. Hyperlipidemia - LDL &gt; 159 mg/dL and/or&#xD;
             HDL &lt; 40 mg/dL (or on prescribed anti-cholesterol treatment) D. Family history of&#xD;
             premature coronary artery disease (CAD) (&lt; 55 years of age in male first-degree&#xD;
             relatives or &lt; 65 years of age in female first degree relatives) E. Diabetes mellitus&#xD;
&#xD;
          3. Any contraindication to zolmitriptan administration including:&#xD;
&#xD;
               -  History of coronary artery disease or coronary vasospasm&#xD;
&#xD;
               -  Symptomatic Wolf-Parkinson-White syndrome or other cardiac accessory conduction&#xD;
                  pathway disorders&#xD;
&#xD;
               -  History of stroke, transient ischemic attack, or hemiplegic or basilar migraine&#xD;
&#xD;
               -  History or current Peripheral Vascular Disease&#xD;
&#xD;
               -  History or current Ischemic bowel disease&#xD;
&#xD;
               -  Hypertension (greater than or equal to 140/90 mmHg at either the screening or&#xD;
                  admission/baseline visit&#xD;
&#xD;
               -  Any history of hepatic impairment defined as ALT &gt; 150 U/L, AST &gt; 130 U/L or&#xD;
                  bilirubin &gt; 2 times the ULN&#xD;
&#xD;
          4. History of contact dermatitis or known dermatological disorders that would interfere&#xD;
             with the study procedures or assessments&#xD;
&#xD;
          5. Planned participation in activities which cause inflammation, irritation, sunburn,&#xD;
             lesions, or tattoos at the intended application sites from 2 weeks prior to dosing&#xD;
             through the duration of the trial&#xD;
&#xD;
          6. Use of any prescription anticoagulant within 30 days prior to the first dose through&#xD;
             the duration of the trial&#xD;
&#xD;
          7. Use of prescription and over the counter medications within one week of dosing other&#xD;
             than the following:&#xD;
&#xD;
               -  Hormone Replacement Therapy (HRT)&#xD;
&#xD;
               -  Non-oral hormonal birth control such as patches, IUD, rings, injections, or&#xD;
                  implants (all non-oral hormonal contraceptives) are allowed provided the dose has&#xD;
                  been stable for at least three months prior to screening and may be continued&#xD;
                  throughout the study&#xD;
&#xD;
               -  Antihistamines&#xD;
&#xD;
               -  Intermittently used NSAIDS&#xD;
&#xD;
               -  Acetaminophen if medically necessary (not more than 1000 mg/day)&#xD;
&#xD;
          8. Current known allergy or sensitivity to zolmitriptan or its derivatives or&#xD;
             formulations&#xD;
&#xD;
          9. Current known allergy or sensitivity to tapes or adhesives&#xD;
&#xD;
         10. Use of any other investigational compound within 30 days of planned study drug dosing&#xD;
&#xD;
         11. Current use or history of drug and/or alcohol abuse within 6 months of screening and&#xD;
             deemed to be clinically significant by the investigator&#xD;
&#xD;
         12. History of nasal pathology (e.g., polyps, significant septal deviation or perforation)&#xD;
             or abnormal nasal exam (with findings such as nose piercing, gross deformities, and/or&#xD;
             severe congestion) deemed to be clinically significant by the investigator&#xD;
&#xD;
         13. Body Mass Index (BMI) lower than 18 kg/m2 or greater than 35 kg/m2&#xD;
&#xD;
         14. In the opinion of the investigator, the subject is not suitable for the study&#xD;
&#xD;
         15. Any positive urine drug result or alcohol test at screening or admission, and/or a&#xD;
             positive COVID-19 test performed at admission.&#xD;
&#xD;
         16. Any planned COVID-19 vaccination within a week of dosing through the duration of the&#xD;
             trial&#xD;
&#xD;
         17. Currently a smoker or a nicotine user&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Kellerman, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Zosano Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy</keyword>
  <keyword>Volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolmitriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

